Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Mar 28, 2021 3:29am
178 Views
Post# 32894293

RE:RE:RE:RE:RE:RE:RE:RE:Once the sites are open there is a screening period-28 days.

RE:RE:RE:RE:RE:RE:RE:RE:Once the sites are open there is a screening period-28 days.

CancerSlayer wrote: "Anyone correct me if I'm wrong...but my math tells me that there were 6 non CRs of a total of 14 that were reported in the quarterly...four were reported to have been removed based on the "old/flawed" definition of treatment eligibility.  And the others didn't get a first treatment that was optimized."

Non CRs = non-responders....of the 6 non-responders, four were previously removed based on the old withdrawal criteria.  I assume one was removed due to either metastatic disease or local progression, & the final one was reported as a non-responder at the 180 day assessment.  This non-responder is still eligible for a 2nd treatment (i.e. having unchanged CIS disease) & could still become CR after a 2nd treatment.  And based on the current protocol/withdrawal definitions, the four previously removed would have also qualified for a 2nd treatment & could have achieved a CR.  So, 5 of the 6 so called non-responders may have technically achieved a CR.  That's a possible 11 for 12 CR rate (or 92% CR) for that first group of 12.



 

Furthermore, if all nine patients reported at the 180 day assessment remain or become CR (includes the two TBDs, two partial responders & the one non-responder) & the "optimized" patients #15 to 25 also achieve CR, our CR rate would still be "80%" (20/25)...& that includes the 4 patients initially removed those who were under-treated.  If you exclude the 4 initially removed, the CR = 95% (19/20).  And considering if all had been optimally treated from the get go....100%.  Why not?  Just my hypothetical opinion.

<< Previous
Bullboard Posts
Next >>